Targets › CEACAM5
25 programs from 22 companies in 41 trials: 32 Phase 1, 6 Phase 3, 3 Phase 2; Oncology, Gastroenterology, Immunology; next expected readout Dec 2026.
Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression. Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. (UniProt, P06731)
Open in Phaseline: the race on CEACAM5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Genmab | Petosemtamab (MCLA-158) bispecific antibody targeting EGFR and LGR5 | EGFR, CEACAM5, LGR5 | Phase 3 | Head and Neck Squamous Cell Carcinoma; Colorectal Cancer; Left-sided Colorectal Cancer; Advanced/Metastatic Solid Tumors | Jan 2028 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Cefixime Bacterial penicillin-binding protein inhibitor | CEACAM5 | Phase 3 | Liver Abscess | – |
| Surgimab | SGM-101 Fluorochrome-labeled anti-CEA monoclonal antibody | CEACAM5 | Phase 3 | Colorectal Neoplasms | – |
| Leiden University Medical Center | SGM-101 CEA-targeted near-infrared fluorophore | CEACAM5 | Phase 2 | Pancreas Adenocarcinoma | Dec 2026 |
| LaNova Medicines | LM-24C5 Anti-CEACAM5 antibody or antibody-drug conjugate | CEACAM5 | Phase 2 | Advanced Solid Tumor Cancer; Advanced Solid Tumor | Dec 2026 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Becotatug Vedotin Anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 2 | Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Mar 2027 |
| A2 Biotherapeutics | A2B530 Logic-gated CAR T-cell targeting CEA; selective activation in HLA-A*02 negative cells | CEACAM5 | Phase 1 | Solid Tumor, Adult | Dec 2026 |
| The First People's Hospital of Changzhou | CEA Specific AAV-DC-CTL CEA-specific cytotoxic T lymphocytes generated from dendritic cells infected with recombin | CEACAM5 | Phase 1 | Gastric Cancer | Dec 2026 |
| Changhai Hospital | Anti-CEA CAR-T Cells CAR-T cell therapy targeting carcinoembryonic antigen (CEA) | CEACAM5 | Phase 1 | Colorectal Cancer | Dec 2026 |
| Chongqing Precision Biotech | CD19 and CD22 targeted prime CAR-T cells CAR-T cell therapy targeting CEA (CEACAM5) | CD19, CEACAM5 | Phase 1 | B-ALL; Advanced Lung Cancer; Systemic Lupus Erythematosus | Dec 2026 |
| Chongqing Precision Biotech | CEA-targeted CAR-T cells anti-CEA chimeric antigen receptor T cell therapy | CEACAM5 | Phase 1 | Gastric Cancer; Colorectal Cancer; Lung Cancer; Peritoneal Metastases From Colorectal Cancer … | Dec 2026 |
| Beijing Biotech | EB-DUO-CAR-NK-CEA/GCC Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H | CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15 | Phase 1 | Colorectal Cancer; Colorectal Cancer Metastatic | Mar 2027 |
| Beijing Biotech | EB-HC01 dual-target CAR-NK cells Allogeneic dual-target CAR-NK cells targeting HER2 and CEA/CEACAM5 | ERBB2, CEACAM5 | Phase 1 | Cholangiocarcinoma | Mar 2027 |
| City of Hope Medical Center | Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A Anti-CEA antibody-drug conjugate targeting CEA-positive cancer cells, delivering alpha-par | CEACAM5 | Phase 1 | Advanced Cancer | Sep 2027 |
| Weijia Fang, MD | FAST CEA-targeted CAR-T (PTC13) anti-CEA CAR-T cell therapy | CEACAM5 | Phase 1 | Colorectal Cancer | Dec 2027 |
| Kivu Bioscience | KIVU-305 CEACAM5-directed antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | Dec 2027 |
| Merck KGaA | M9140 anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Colorectal Cancer; Solid Tumors | Dec 2027 |
| Fortvita Biologics (USA)Inc. | IBI3020 anti-CEACAM5 monoclonal antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | Dec 2027 |
| Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Ifinatamab Deruxtecan (I-DXd, DS-7300a, MK-2400) Anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Small-Cell Lung Cancer | Jan 2028 |
| Adlai Nortye Biopharma | AN4035 CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload | CEACAM5, KRAS, NRAS, HRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2028 |
| Pfizer | PF-08046050 CEACAM5-targeting antibody-drug conjugate | CEACAM5 | Phase 1 | Colorectal Neoplasms | Sep 2029 |
| Bristol-Myers Squibb | BMS-986490 anti-CEACAM5 antibody | CEACAM5 | Phase 1 | Advanced Solid Tumors | Dec 2029 |
| Roche | SPLIT Abs (RO7782304, RO7782306) CEA-targeting pretargeting antibody for radioimmunotherapy | CEACAM5 | Phase 1 | Metastatic Colorectal Cancer | Feb 2034 |
| Harbour BioMed (Guangzhou) | HBM4003 (Porustobart) Anti-CEACAM5 antibody | CEACAM5 | Phase 1 | Solid Tumors | – |
| Merck KGaA | M9140 anti-CEACAM5 antibody-drug conjugate | CEACAM5 | Phase 1 | Solid Tumors | – |
Colorectal Cancer (6) Solid Tumors (5) Advanced Lung Cancer (4) Gastric Cancer (2) Head and Neck Squamous Cell Carcinoma (2) Colorectal Neoplasms (2) Lung Cancer (1) Peritoneal Metastases From Colorectal Cancer (1) NSCLC (Advanced Non-small Cell Lung Cancer) (1) Solid Tumor, Adult (1) Metastatic Colorectal Cancer (1) Advanced Solid Tumors (1)
small molecule (7), antibody (7), other (4), mixed (4), protein or peptide (2)
Chongqing Precision Biotech (2) Beijing Biotech (2) Merck KGaA (2) A2 Biotherapeutics (1) Roche (1) Bristol-Myers Squibb (1) Post Graduate Institute of Medical Education and Research, Chandigarh (1) LaNova Medicines (1) Weijia Fang, MD (1) Genmab (1) Changhai Hospital (1) Harbour BioMed (Guangzhou) (1) Kivu Bioscience (1) Leiden University Medical Center (1) Fortvita Biologics (USA)Inc. (1) Pfizer (1) Surgimab (1) Adlai Nortye Biopharma (1) City of Hope Medical Center (1) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
ERBB2 (2) GUCY2C (1) CEA (1) HER2 (1) IL15 (1) EGFR (1) LGR5 (1) CD19 (1) KRAS (1) NRAS (1) HRAS (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.